Financial Strategy - Orsted 计划发行 94 亿美元（$9.4 billion）的股票[1] Project Funding - 该融资用于海上风电项目[1]

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].